Osteochondrosis: Pathogenetic Bioregulatory Limitations of Using the Drug Discus Compositum
| Autor: | L.О. Vakulenko, S.V. Popovych |
|---|---|
| Jazyk: | English<br />Ukrainian |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Bolʹ, Sustavy, Pozvonočnik, Vol 6, Iss 2.22, Pp 47-51 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2224-1507 2307-1133 |
| DOI: | 10.22141/2224-1507.2.22.2016.75761 |
| Popis: | Treatment of osteochondrosis is one of the actual problems in the therapy of degenerative-dystrophic diseases of the musculoskeletal system [1]. The clinical studies have shown that osteochondrosis — a disease of the whole body, and therefore, interdisciplinary problem, relevant both for neurologists, as well as for orthopedists and general practitioners [2]. A brief review of clinical studies is presented demonstrating the relevance of using bioregulatory approach, Discus compositum and other combined bioregulatory drugs (CBD) [3–6]. The feature of CBD — the content of ultra-low doses (low dose, very-low dose antigen) of active substances that contribute to the recovery of the processes of self-regulation and detoxification in the body, activation of metabolism and regeneration/reparation processes. Bioregulatory action of CBD complements the effect of other medicines, combining well with them. Since the ultra-small doses are not metabolized in the body, CBD have no pharmacokinetics: they do not require additional energy and do not have a pharmacological stress on the body [3–6]. In this regard, they are well-tolerated by patients during chronic administration. Also, their application is helpful, if there are contraindications, side effects and the risk of complications when using other groups of drugs. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|